Cargando…

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

Somatic mutations in isocitrate dehydrogenase 2 (IDH2) contribute to the pathogenesis of acute myeloid leukemia (AML) through production of the oncometabolite 2-hydroxyglutarate (2HG)(1–8). Enasidenib (AG-221) is an allosteric inhibitor that binds to the IDH2 dimer interface and blocks 2HG productio...

Descripción completa

Detalles Bibliográficos
Autores principales: Intlekofer, Andrew M., Shih, Alan H., Wang, Bo, Nazir, Abbas, Rustenburg, Ariën S., Albanese, Steven K., Patel, Minal, Famulare, Christopher, Correa, Fabian M., Takemoto, Naofumi, Durani, Vidushi, Liu, Hui, Taylor, Justin, Farnoud, Noushin, Papaemmanuil, Elli, Cross, Justin R., Tallman, Martin S., Arcila, Maria E., Roshal, Mikhail, Petsko, Gregory A., Wu, Bin, Choe, Sung, Konteatis, Zenon D., Biller, Scott A., Chodera, John D., Thompson, Craig B., Levine, Ross L., Stein, Eytan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121718/
https://www.ncbi.nlm.nih.gov/pubmed/29950729
http://dx.doi.org/10.1038/s41586-018-0251-7
_version_ 1783352529312022528
author Intlekofer, Andrew M.
Shih, Alan H.
Wang, Bo
Nazir, Abbas
Rustenburg, Ariën S.
Albanese, Steven K.
Patel, Minal
Famulare, Christopher
Correa, Fabian M.
Takemoto, Naofumi
Durani, Vidushi
Liu, Hui
Taylor, Justin
Farnoud, Noushin
Papaemmanuil, Elli
Cross, Justin R.
Tallman, Martin S.
Arcila, Maria E.
Roshal, Mikhail
Petsko, Gregory A.
Wu, Bin
Choe, Sung
Konteatis, Zenon D.
Biller, Scott A.
Chodera, John D.
Thompson, Craig B.
Levine, Ross L.
Stein, Eytan M.
author_facet Intlekofer, Andrew M.
Shih, Alan H.
Wang, Bo
Nazir, Abbas
Rustenburg, Ariën S.
Albanese, Steven K.
Patel, Minal
Famulare, Christopher
Correa, Fabian M.
Takemoto, Naofumi
Durani, Vidushi
Liu, Hui
Taylor, Justin
Farnoud, Noushin
Papaemmanuil, Elli
Cross, Justin R.
Tallman, Martin S.
Arcila, Maria E.
Roshal, Mikhail
Petsko, Gregory A.
Wu, Bin
Choe, Sung
Konteatis, Zenon D.
Biller, Scott A.
Chodera, John D.
Thompson, Craig B.
Levine, Ross L.
Stein, Eytan M.
author_sort Intlekofer, Andrew M.
collection PubMed
description Somatic mutations in isocitrate dehydrogenase 2 (IDH2) contribute to the pathogenesis of acute myeloid leukemia (AML) through production of the oncometabolite 2-hydroxyglutarate (2HG)(1–8). Enasidenib (AG-221) is an allosteric inhibitor that binds to the IDH2 dimer interface and blocks 2HG production by IDH2 mutants(9,10). In a phase I/II clinical trial, enasidenib inhibited 2HG production and induced clinical responses in relapsed/refractory IDH2-mutant AML(11). Here we describe two patients with IDH2-mutant AML who had a clinical response to enasidenib followed by clinical resistance, disease progression, and recurrent elevation in circulating 2HG. We found that therapeutic resistance was associated with the emergence of second-site IDH2 mutations in trans, such that resistance mutations occurred in the IDH2 allele without the neomorphic R140Q mutation. The in trans mutations occurred at glutamine 316 (Q316E) and isoleucine 319 (I319M), which are at the interface where enasidenib binds the IDH2 dimer. Expression of these mutant disease alleles alone did not induce 2HG production, however expression of Q316E and I319M mutations in concert with IDH2 R140Q in trans allowed for 2HG production that was resistant to inhibition by enasidenib. Biochemical studies predicted that resistance to allosteric IDH inhibitors could also occur via IDH dimer-interface mutations in cis, which was confirmed in a patient with acquired resistance to the IDH1 inhibitor ivosidenib (AG-120). Our observations elucidate a novel mechanism of acquired resistance to a targeted therapy and underscore the importance of 2HG production to the pathogenesis of IDH-mutant malignancies.
format Online
Article
Text
id pubmed-6121718
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-61217182018-12-27 Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations Intlekofer, Andrew M. Shih, Alan H. Wang, Bo Nazir, Abbas Rustenburg, Ariën S. Albanese, Steven K. Patel, Minal Famulare, Christopher Correa, Fabian M. Takemoto, Naofumi Durani, Vidushi Liu, Hui Taylor, Justin Farnoud, Noushin Papaemmanuil, Elli Cross, Justin R. Tallman, Martin S. Arcila, Maria E. Roshal, Mikhail Petsko, Gregory A. Wu, Bin Choe, Sung Konteatis, Zenon D. Biller, Scott A. Chodera, John D. Thompson, Craig B. Levine, Ross L. Stein, Eytan M. Nature Article Somatic mutations in isocitrate dehydrogenase 2 (IDH2) contribute to the pathogenesis of acute myeloid leukemia (AML) through production of the oncometabolite 2-hydroxyglutarate (2HG)(1–8). Enasidenib (AG-221) is an allosteric inhibitor that binds to the IDH2 dimer interface and blocks 2HG production by IDH2 mutants(9,10). In a phase I/II clinical trial, enasidenib inhibited 2HG production and induced clinical responses in relapsed/refractory IDH2-mutant AML(11). Here we describe two patients with IDH2-mutant AML who had a clinical response to enasidenib followed by clinical resistance, disease progression, and recurrent elevation in circulating 2HG. We found that therapeutic resistance was associated with the emergence of second-site IDH2 mutations in trans, such that resistance mutations occurred in the IDH2 allele without the neomorphic R140Q mutation. The in trans mutations occurred at glutamine 316 (Q316E) and isoleucine 319 (I319M), which are at the interface where enasidenib binds the IDH2 dimer. Expression of these mutant disease alleles alone did not induce 2HG production, however expression of Q316E and I319M mutations in concert with IDH2 R140Q in trans allowed for 2HG production that was resistant to inhibition by enasidenib. Biochemical studies predicted that resistance to allosteric IDH inhibitors could also occur via IDH dimer-interface mutations in cis, which was confirmed in a patient with acquired resistance to the IDH1 inhibitor ivosidenib (AG-120). Our observations elucidate a novel mechanism of acquired resistance to a targeted therapy and underscore the importance of 2HG production to the pathogenesis of IDH-mutant malignancies. 2018-06-27 2018-07 /pmc/articles/PMC6121718/ /pubmed/29950729 http://dx.doi.org/10.1038/s41586-018-0251-7 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Intlekofer, Andrew M.
Shih, Alan H.
Wang, Bo
Nazir, Abbas
Rustenburg, Ariën S.
Albanese, Steven K.
Patel, Minal
Famulare, Christopher
Correa, Fabian M.
Takemoto, Naofumi
Durani, Vidushi
Liu, Hui
Taylor, Justin
Farnoud, Noushin
Papaemmanuil, Elli
Cross, Justin R.
Tallman, Martin S.
Arcila, Maria E.
Roshal, Mikhail
Petsko, Gregory A.
Wu, Bin
Choe, Sung
Konteatis, Zenon D.
Biller, Scott A.
Chodera, John D.
Thompson, Craig B.
Levine, Ross L.
Stein, Eytan M.
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
title Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
title_full Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
title_fullStr Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
title_full_unstemmed Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
title_short Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
title_sort acquired resistance to idh inhibition through trans or cis dimer-interface mutations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121718/
https://www.ncbi.nlm.nih.gov/pubmed/29950729
http://dx.doi.org/10.1038/s41586-018-0251-7
work_keys_str_mv AT intlekoferandrewm acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT shihalanh acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT wangbo acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT nazirabbas acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT rustenburgariens acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT albanesestevenk acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT patelminal acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT famularechristopher acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT correafabianm acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT takemotonaofumi acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT duranividushi acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT liuhui acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT taylorjustin acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT farnoudnoushin acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT papaemmanuilelli acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT crossjustinr acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT tallmanmartins acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT arcilamariae acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT roshalmikhail acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT petskogregorya acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT wubin acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT choesung acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT konteatiszenond acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT billerscotta acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT choderajohnd acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT thompsoncraigb acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT levinerossl acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations
AT steineytanm acquiredresistancetoidhinhibitionthroughtransorcisdimerinterfacemutations